Related Experiment Video
Updated: Mar 19, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.6K
Adapting Glucagon-Like Peptide-1 Receptor Agonists for Innovative Psoriasis Therapy
Erika Tanquilut1, Madeleine Dumke1, Andres Parga2
1Arizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ, USA.
Journal of Cutaneous Medicine and Surgery
|March 18, 2026
Summary
Glucagon-like peptide-1 (GLP-1) receptor agonists show promise as an adjunctive therapy for psoriasis, potentially managing inflammation. Further research is needed to confirm effectiveness due to current study limitations.
Area of Science:
- Dermatology
- Endocrinology
- Immunology
Background:
- Psoriasis is a chronic, immune-mediated skin condition affecting many patients.
- Current treatments focus on immunosuppression and immune modulation.
- Emerging evidence suggests a potential role for GLP-1 receptor agonists in managing psoriatic inflammation.
Purpose of the Study:
- To review and analyze existing literature on GLP-1 receptor agonists for psoriasis treatment.
- To evaluate the efficacy of this therapeutic approach.
- To identify limitations in current research regarding GLP-1 receptor agonists and psoriasis.
Main Methods:
- Literature review synthesizing case reports, cohort studies, and clinical trials.
- Analysis of clinical outcomes, proposed mechanisms of action, and patient populations.
- Characterization of existing research on GLP-1 receptor agonists in psoriasis management.
Main Results:
- Preliminary evidence suggests GLP-1 receptor agonists may be beneficial as an adjunctive treatment for psoriasis.
- Identified limitations include small sample sizes, varied study designs, and inconsistent follow-up periods.
- Lack of randomized controlled trials was noted as a significant gap in the current research.
Conclusions:
- GLP-1 receptor agonists show potential as a novel therapeutic option for psoriasis.
- Further rigorous research, including randomized controlled trials, is essential to confirm efficacy and define their role.
- Addressing research gaps will clarify the use of GLP-1 receptor agonists in managing this chronic inflammatory skin disease.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.2K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
01:06Oral Hypoglycemic Agents: Glinides
879
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
879
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
588
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
588
01:23Dipeptidyl Peptidase 4 Inhibitors
934
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
934
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
871
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
871
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
808
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
808